Drug intelligence / Profile preview

didesmethyl-cariprazine

Development stage: Unknown
Lead developer: Gedeon Richter
Modality: Small Molecules
Administration: Oral

Overview

Didesmethyl-cariprazine (DDCAR) is a major, orally active, and blood-brain barrier-permeable active metabolite of the atypical antipsychotic cariprazine. It acts as a partial agonist at dopamine D2 and D3 receptors, a full agonist at the serotonin 5-HT1A receptor, and an antagonist at the serotonin 5-HT2A and 5-HT2B receptors. With a long half-life of 1-3 weeks, DDCAR plays a significant role in the sustained therapeutic effects of cariprazine, which is used in the treatment of schizophrenia, bipolar I disorder, and major depressive disorder.

Other names: N-Didesmethyl Cariprazine

Targets

HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2B (5-Hydroxytryptamine Receptor 2B)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)

Beyond the preview

Go deeper on didesmethyl-cariprazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on didesmethyl-cariprazine.

Explore the full profile